Literature DB >> 7783275

Coxiella burnetii antibody prevalences among human populations in north-east Africa determined by enzyme immunoassay.

B A Botros1, A K Soliman, A W Salib, J Olson, R G Hibbs, J C Williams, M Darwish, A el Tigani, D M Watts.   

Abstract

Retrospective serosurveys were conducted to determine the prevalence of antibody to phase-I Coxiella burnetii among humans in various locations of north-east Africa. Sera were tested by the enzyme immunoassay (EIA). Initially the EIA was compared with the standard indirect fluorescent antibody (IFA) method for the detection of antibody to C. burnetii. Results indicated that the EIA was slightly less sensitive (88%), but highly specific (94%) and less subjective than the IFA technique. EIA was subsequently adopted for estimating prevalences in the studied human populations. Data obtained by EIA indicated that the prevalence of C. burnetii antibody among adult Egyptian blood donors was 20% (n = 358) in the Suez Canal area, 16% (n = 501) in the Nile Valley and 10% (n = 427) in the Nile Delta. Among adult patients with acute, undifferentiated fever in Egypt, the prevalence was 28% (n = 50) of acute sera, with seroconversion in 12% of convalescent sera. Antibody to C. burnetii was detected by EIA in the sera of 25% (n = 71) of cattle workers in Egypt, 10% (n = 100) of housewives in Sudan, and 37% (n = 104) of adults in north-west Somalia. Following a fever outbreak affecting all ages in northern Sudan, IgG antibody to C. burnetii was present in 54% of the febrile persons (n = 185) and in 53% of afebrile persons (n = 186). IgM antibody to C. burnetii was demonstrated in 29% of the febrile persons and 15% of the afebrile persons. These results implicate C. burnetii as a possibly important and under-reported cause of human disease and undiagnosed fevers in north-east Africa.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7783275

Source DB:  PubMed          Journal:  J Trop Med Hyg        ISSN: 0022-5304


  8 in total

1.  Cross-sectional study for determining the prevalence of Q fever in small ruminants and humans at El Minya Governorate, Egypt.

Authors:  Mostafa F N Abushahba; Abdelbaset E Abdelbaset; Mohamed S Rawy; Sylvia O Ahmed
Journal:  BMC Res Notes       Date:  2017-10-30

Review 2.  A Comprehensive Review of Common Bacterial, Parasitic and Viral Zoonoses at the Human-Animal Interface in Egypt.

Authors:  Yosra A Helmy; Hosny El-Adawy; Elsayed M Abdelwhab
Journal:  Pathogens       Date:  2017-07-21

3.  A systematic review and meta-analysis of the aetiological agents of non-malarial febrile illnesses in Africa.

Authors:  Martin Wainaina; David Attuy Vey da Silva; Ian Dohoo; Anne Mayer-Scholl; Kristina Roesel; Dirk Hofreuter; Uwe Roesler; Johanna Lindahl; Bernard Bett; Sascha Al Dahouk
Journal:  PLoS Negl Trop Dis       Date:  2022-01-24

4.  High Prevalence and New Genotype of Coxiella burnetii in Ticks Infesting Camels in Somalia.

Authors:  Dimitrios Frangoulidis; Claudia Kahlhofer; Ahmed Shire Said; Abdinasir Yusuf Osman; Lidia Chitimia-Dobler; Yassir Adam Shuaib
Journal:  Pathogens       Date:  2021-06-12

5.  Q fever in cattle in some Egyptian Governorates: a preliminary study.

Authors:  Mayada Gwida; Maged El-Ashker; Mohamed El-Diasty; Christina Engelhardt; Iahtasham Khan; Heinrich Neubauer
Journal:  BMC Res Notes       Date:  2014-12-07

Review 6.  Q fever is an old and neglected zoonotic disease in Kenya: a systematic review.

Authors:  J Njeru; K Henning; M W Pletz; R Heller; H Neubauer
Journal:  BMC Public Health       Date:  2016-04-05       Impact factor: 3.295

7.  Q fever: A neglected disease of camels in Giza and Cairo Provinces, Egypt.

Authors:  Hend H A M Abdullah; Hany A Hussein; Khaled A Abd El-Razik; Ashraf M A Barakat; Yousef A Soliman
Journal:  Vet World       Date:  2019-12-12

8.  Multiple vector-borne pathogens of domestic animals in Egypt.

Authors:  Hend H A M Abdullah; Nadia Amanzougaghene; Handi Dahmana; Meriem Louni; Didier Raoult; Oleg Mediannikov
Journal:  PLoS Negl Trop Dis       Date:  2021-09-29
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.